Antiretroviral therapy in HIV-infected patients: A proposal to assess the economic value of the single-tablet regimen

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 59-68

  Colombo, Giorgio L ^a,b   Di Matteo, Sergio ^b   Maggiolo, Franco ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b Studi Analisi Valutazioni Economiche   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

Adherence; Efavirenz; Emtricitabine; Highly active antiretroviral therapy; Pharmacoeconomics; Quality of life; Single tablet regimen; Tenofovir

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; POLYPHARMACY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TABLET FORMULATION;

EID: 84873935810     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S38977     Document Type: Article

References (50)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372: 293-299.
2. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62.
3. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
4. Ministry of Health, National Committee on AIDS. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 -Luglio 2012. Italian.
5. Burgoyne RW, Tan DH. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother. 2008;61:469-473.
6. Camacho R, Teófilo E. Antiretroviral therapy in treatment-naïve patients with HIV infection. Curr Opin HIV AIDS. 2011;6 Suppl 1:S3-S11.
7. Nachega JB, Rosenkranz B, Pham PA. Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden? Patient Prefer Adherence. 2011;5:645-651.
8. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484-488.
9. Pulido F, Ribera E, Moreno S, et al. Once-daily antiretroviral therapy: Spanish consensus statement. J Antimicrob Chemother. 2005;56: 808-818.
10. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials. 2002;5:371-378.
11. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
12. Boyle B, Jayaweera D, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9:164-176.
13. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-125.
14. Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 2011;3:197-205.
15. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. New York, NY: Oxford University Press; 2006.
16. Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27:159-165.
17. Garattini L, Tediosi F, Di Cintio E, Yin D, Parazzini F; Gruppo di Studio ARCA (AIDS Resources and Costs Analysis). Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:733-741.
18. Italian Health Economics Association. Italian guidelines proposal on how to conduct economic evaluation studies of health programs. Pharmacoeconomics. 2009;11:83-93. Italian.
19. Regione Emilia-Romagna. Lo stato dell'infezione da hiv/aids in emilia-romagna Aggiornamento sull'epidemia e primi risultati del sistema di sorveglianza dell'infezione da HIV al 31/12/2008. Italian.
20. Gallant JE, DeJesus E, Arribas JR, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
21. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
22. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-78.
23. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV irtfection. HIV Clin Trials. 2004;5:294-304.
24. http://www.euroqol.org. Accessed May 2012.
25. AIFA Italian Medicines Agency. Available from: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0. Accessed May 2012.
26. ISTAT. Availbale from: http://www.istat.it/prezzi/precon/dati/. Accessed May 2012.
27. Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
28. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess. 1999;3: 1-134.
29. Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care. Merging Theory with Practice. Oxford, UK: Oxford University Press; 2001.
30. World Health Organization. Adherence to long-term therapies: evidence for action. WHO report MNC/03/01. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed December 7, 2012.
31. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
32. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
33. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20:2051-2064.
34. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort study. J Acquir Immune Defic Syndr. 2006;41:385-392.
35. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
36. Deschamps AE, De Graeve V, Van Wijngaerden E, et al. Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using medication event monitoring system. AIDS Patient Care STDS. 2004;18:644-657.
37. Diabate S, Alary M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS. 2007;21:1799-1803.
38. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
39. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529-536.
40. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials. 2002;5:371-378.
41. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311-1316.
42. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
43. Trotta MP, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than those receiving protease inhibitor-containing regimens. AIDS. 2003;17:1099-1102.
44. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-29.
45. Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7:e31591.
46. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24:2835-2840.
47. Sterrantino G, Santoro L, Bartolozzi D, et al. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Prefer Adherence. 2012;6:427-433.
48. Woo G, Tomlinson G, Yim C, et al. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol. 2012;26: 445-451.
49. Buitinga L, Braakman-Jansen LM, Taal E, et al. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res (Hoboken). 2012;64:826-332.
50. Di Biagio A, Prinapori R, Giannarelli D, et al; on behalf of the ARCA Collaborative Group. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother. August 25, 2012. [Epub ahead of print.]